Of note, human iPSCs from patients with sporadic Alzheimer’s disease (sAD) and familial Alzheimer’s disease (fAD) enhance MMP-2 and MMP-9 production, which leads to tau degradation, in both its monomeric and pathologically aggregated forms [228]. Here, MAPT is linked to familial Alzheimer disease.